Table 5.
N (%) | Tumor circularity | P value | |
---|---|---|---|
Means, standard deviation | |||
Histological type | 0.997 | ||
IDC | 117 (78) | 56.7 ± 1.2 | |
Non-IDC | 33 (22) | 57.0 ± 2.2 | |
Pathological grade | 0.001* | ||
low | 13 (8.7) | 53.9 ± 3.7 | |
intermediate | 63 (42) | 52.8 ± 1.5 | |
high | 67 (44.7) | 60.9 ± 1.4 | |
N/A | 7 (4.7) | ||
axillary lymph node involvement | 0.293 | ||
positive | 48 (32) | 58.3 ± 2.0 | |
negative | 102 (68) | 55.9 ± 1.2 | |
Tumor size (mm) | 0.012* | ||
<15 | 25 (16.7) | 63.0 ± 2.3 | |
15~24 | 64 (42.7) | 57.4 ± 1.3 | |
25~35 | 43 (28.7) | 54.5 ± 2.2 | |
>35 | 18 (12) | 51.6 ± 3.3 | |
ER subset | <0.001* | ||
negative | 38 (25.3) | 67.0 ± 1.7 | |
positive | 28 (18.7) | 57.1 ± 2.2 | |
strongly positive | 84 (56) | 51.9 ± 1.2 | |
PR subset | <0.001* | ||
negative | 59 (39.3) | 64.3 ± 1.5 | |
positive | 41 (27.3) | 53.1 ± 1.7 | |
strongly positive | 50 (33.3) | 50.7 ± 1.5 | |
Ki67 subset | 0.004* | ||
low | 33 (22) | 52.8 ± 1.7 | |
intermediate | 66 (44) | 54.6 ± 1.5 | |
high | 51 (34) | 62.0 ± 1.9 | |
HER-2 group | 0.525 | ||
non-expression | 57 (38) | 58.9 ± 1.8 | |
low-expression | 58 (38.7) | 55.2 ± 1.5 | |
overexpression | 35 (23.3) | 55.8 ± 2.2 | |
Molecular subtype | <0.001* | ||
luminal A | 43 (28.7) | 54.7 ± 1.5 | |
luminal B | 69 (46) | 52.3 ± 1.5 | |
HER2-overexpressed | 16 (10.7) | 61.6 ± 3.2 | |
TNBC | 22 (14.7) | 70.8 ± 1.4 |
*P < 0.05.